资金流向方面，今日主力资金净流入1691.18万元，占比成交额11.75%。其中，超大单净流入939.12万 元、占成交额6.53%，大单净流入752.06万元、占成交额5.23%，中单净流出流出1224.94万元、占成交 额8.51%，小单净流出466.24万元、占成交额3.24%。 毕得医药最新一期业绩显示，截至2025一季报，公司营业总收入2.96亿元、同比增长12.83%，归属净利 润3069.31万元，同比增长17.71%，扣非净利润2807.51万元，同比增长10.40%，流动比率2.876、速动比 率1.525、资产负债率23.82%。 天眼查商业履历信息显示，上海毕得医药科技股份有限公司，成立于2007年，位于上海市，是一家以从 事研究和试验发展为主的企业。企业注册资本9088.2948万人民币，实缴资本6057.4693万人民币。公司 法定代表人为戴岚。 金融界消息 截至2025年7月29日收盘，毕得医药（688073）报收于61.48元，上涨4.33%，换手率 5.46%，成交量2.36万手，成交金额1.44亿元。 来源：金融界 通过天眼查大数据分析，上海毕得医药科技股份有限公司共对外投资 ...

Company Overview - Bid Pharma, established in 2007 and headquartered in Shanghai, focuses on the research, production, sales, and custom synthesis of pharmaceutical intermediates [1] Stock Performance - Bid Pharma has experienced a decline in stock price for five consecutive trading days, with a cumulative drop of -3.54% [1] Fund Holdings - China Europe Fund's China Europe Medical Health Mixed A is among the top ten shareholders of Bid Pharma, maintaining its position in the second quarter of this year [2] - The fund has achieved a year-to-date return of 19.65%, ranking 909 out of 4513 in its category [2] Fund Performance Comparison - The performance of China Europe Medical Health Mixed A fund shows a year-to-date increase of 19.65%, compared to the category average of 13.49% and the CSI 300 index's 5.44% [3] Fund Manager Profiles - The fund is managed by Guo Lan, who has a Ph.D. in Biomedical Engineering from Northwestern University and has been with China Europe Fund since October 2014 [4][5] - Zhao Lei, who has a master's degree and previously worked as a researcher in the pharmaceutical and biotechnology sector, joined China Europe Fund in May 2021 and became a fund manager on July 4, 2025 [6] Fund Management Details - Guo Lan has managed multiple funds and has a total fund size of 399.08 billion with a return of 106.72% [5] - Zhao Lei currently manages two funds with a total size of 308.01 billion, achieving a return of 8.02% since her appointment [6] Company Structure - China Europe Fund Management Company was established in July 2006 and has 25 shareholders, with WP Asia Pacific Asset Management LLC holding 23.30% [6]

Group 1: Bid Medicine - Bid Medicine emphasizes capital operations and resource integration as key strategic focuses for future development, aiming to expand global business through various means and continuously seek acquisition opportunities [1] - The company has completed its global market layout, established multiple regional centers, and upgraded its U.S. warehouse and R&D center, resulting in rapid growth in overseas business [1] - Bid Medicine is facing a 20% fentanyl tax and a small 10% equivalent tariff on products sold in the U.S., but it has managed to pass on costs through price increases and discount adjustments, leading to minimal impact [1] - The company perceives a gradual recovery in industry demand, with improving orders from overseas and ongoing stimulation of market growth due to domestic innovative drug policies [1] Group 2: Medicy - Medicy is strengthening key technology research for hot drug development and building multiple innovative technology service platforms covering CGT, nucleic acid drugs, and PROTC [2] - The company has taken measures to ensure stable supply of experimental monkeys and has established a research laboratory in Boston, enhancing its overseas market expansion [2] - Medicy is focusing on talent development, optimizing internal organization and talent structure, and aims to improve operational conditions through cost reduction, efficiency enhancement, and strengthened R&D capabilities [2] - The domestic CRO industry is expected to benefit from policy support and the advancement of innovative drug development [2]

上海毕得医药科技股份有限公司 2025 年第四次临时股东大会会议资料 证券代码：688073 证券简称：毕得医药 上海毕得医药科技股份有限公司 2025 年第四次临时股东大会会议资料 2025 年 7 月 | 2025 年第四次临时股东大会会议须知 | 1 | | --- | --- | | 2025 年第四次临时股东大会会议议程 | 4 | | 2025 年第四次临时股东大会会议议案 | 6 | | 案 6 | | | 议案二：关于修改公司部分内部制度的议案 8 | | | 议案三：关于续聘公司 2025 年度审计机构的议案 10 | | 上海毕得医药科技股份有限公司 2025 年第四次临时股东大会会议资料 上海毕得医药科技股份有限公司 2025 年第四次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《上海毕得医药科技股份有限公司章程》等相关规定， 上海毕得医药科技股份有限公司（以下简称"公司"或"毕得医药"）特制定股 东大会会议须知： 一、为确认出席大会的股东或其代 ...

Core Viewpoint - The AI Fund Agricultural Bank Healthcare Stock (000913) reported a profit of 142 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1565 yuan, and a net asset value growth rate of 10.67% during the reporting period [2] Fund Performance - As of the end of Q2 2025, the fund's scale was 1.441 billion yuan [13] - The fund's unit net value as of July 17 was 1.875 yuan [2] - The fund's one-year cumulative net value growth rate was 38.71%, ranking 24 out of 53 comparable funds [2] - The fund's three-month cumulative net value growth rate was 26.79%, ranking 28 out of 54 comparable funds [2] - The fund's six-month cumulative net value growth rate was 42.95%, ranking 22 out of 54 comparable funds [2] - The fund's three-year cumulative net value growth rate was -9.44%, ranking 24 out of 46 comparable funds [2] Risk Metrics - The fund's three-year Sharpe ratio was -0.143, ranking 33 out of 46 comparable funds [7] - The maximum drawdown over the past three years was 40.52%, ranking 23 out of 46 comparable funds [8] - The highest single-quarter maximum drawdown occurred in Q1 2021, at 28.61% [8] Investment Strategy - The fund manager defined investment keywords for 2025 as innovation, medical AI, self-control, and state-owned enterprise reform [2] - The average stock position over the past three years was 90.34%, compared to the industry average of 88.16% [11] - The fund reached its highest stock position of 93.72% at the end of Q3 2020 and its lowest of 84.43% at the end of Q3 2024 [11] Top Holdings - As of the end of Q2 2025, the fund's top ten holdings included companies such as Heng Rui Medicine, Zejing Pharmaceutical, and Xinlitai [15]

Group 1 - The company held its 18th meeting of the second Supervisory Board on July 15, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2] - The Supervisory Board decided to abolish the Supervisory Board and transfer its powers to the Audit Committee of the Board of Directors, in accordance with the new Company Law and the revised Guidelines for Listed Companies [1][2] - The company plans to modify its business scope and amend relevant provisions in its Articles of Association to reflect these changes [1] Group 2 - The company proposed to reappoint Zhonghui Certified Public Accountants as the financial report auditor and internal control auditor for the fiscal year 2025, with audit fees to be negotiated based on market principles [2] - The resolution regarding the reappointment of the auditing firm received unanimous approval from all supervisors and will be submitted to the shareholders' meeting for further consideration [2]

Core Viewpoint - The company establishes an investor relations management system to enhance communication with investors, protect their rights, and improve corporate governance and overall value [2][3][4]. Group 1: Principles of Investor Relations Management - The investor relations management should adhere to compliance, equality, proactivity, and honesty principles [4][7]. - The company must treat all investors equally, especially facilitating participation for small and medium investors [4]. - The management activities should be proactive, listening to investor feedback and responding to their needs [4]. Group 2: Communication Channels and Methods - The company should utilize multiple channels for investor relations, including the official website, new media platforms, and direct communication methods like phone and email [5][6]. - It is essential to establish a dedicated investor relations section on the company website to address inquiries and complaints [6][12]. - The company should organize events such as roadshows and analyst meetings to communicate its situation and gather feedback [6][7]. Group 3: Responsibilities and Management Structure - The board secretary is responsible for coordinating investor relations activities, supported by the securities department for daily management [9][24]. - The company must ensure that all communications are accurate, complete, and comply with legal disclosure obligations [15][26]. - Staff involved in investor relations should possess relevant skills and knowledge, including understanding corporate governance and financial regulations [10][12]. Group 4: Handling Investor Inquiries and Complaints - The company is responsible for addressing investor inquiries and complaints promptly and effectively [21][22]. - It should actively support investor protection organizations and facilitate the exercise of shareholder rights [20][22]. - The company must maintain a clear distinction between promotional materials and independent media reports [9]. Group 5: Documentation and Record-Keeping - The company should maintain comprehensive records of investor relations activities, including participant details and communication content [28]. - All activities should be documented and made available on the designated investor relations platform [28]. Group 6: Implementation and Compliance - The investor relations management system will take effect upon approval by the board and will be revised as necessary [30]. - Any matters not covered by this system will be governed by relevant regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange [29].

Core Viewpoint - The company establishes a long-term mechanism to prevent the controlling shareholder and related parties from occupying company funds, ensuring the safety of company assets and compliance with relevant laws and regulations [1][2][3] Group 1: Mechanism for Prevention - The company aims to prevent both operational and non-operational fund occupation by the controlling shareholder and related parties [1][2] - The company must maintain independence in personnel, assets, and finances from the controlling shareholder and related parties [2][3] - The board of directors and internal institutions should operate independently and manage the company without interference from the controlling shareholder [2][3] Group 2: Fund Management Restrictions - The company is prohibited from providing funds to the controlling shareholder and related parties for non-operational expenses, including wages, benefits, and advertising [2][3] - Strict limitations are placed on the company regarding the provision of guarantees and loans to the controlling shareholder and related parties [3][4] - Any funds occupied by the controlling shareholder must be repaid in cash, with strict controls on non-cash asset repayments [5][6] Group 3: Responsibilities and Oversight - The chairman of the board is the primary responsible person for preventing fund occupation, with specific roles assigned to the board secretary and financial officer [3][4] - Regular inspections by the finance and audit departments are mandated to monitor transactions with the controlling shareholder and related parties [4][5] - Legal actions may be taken against the controlling shareholder if they occupy company funds or assets, including reporting to regulatory authorities [5][6] Group 4: Compliance and Amendments - The company must adhere to national laws and regulations, and any amendments to this system must be reported and approved by the shareholders [7] - The board of directors is responsible for interpreting this system and ensuring compliance with relevant laws [7]

General Principles - The rules are established to clarify the responsibilities and decision-making processes of the company's board of directors, ensuring effective governance and compliance with relevant laws and regulations [2][3][30] Board Composition and Authority - The company is required to establish a board of directors as per the company charter and relevant laws [3][4] - Directors must be natural persons and cannot hold office under certain disqualifying conditions, such as criminal convictions or bankruptcy involvement [4][5] Chairman of the Board - The board elects a chairman from among its members, who is responsible for presiding over meetings and ensuring the execution of board resolutions [6][7] Board Secretary - The company appoints a board secretary responsible for preparing meetings, managing documents, and handling information disclosure [9][10] - The board secretary must meet specific qualifications, including professional knowledge and experience [10][11] Board Committees - The board establishes specialized committees, including an audit committee, a strategy committee, a nomination committee, and a compensation committee, each with defined responsibilities [11][12][13][14] - The audit committee is tasked with reviewing financial information and overseeing audit processes [11][12] Meeting Procedures - The board must hold at least two regular meetings annually, with specific procedures for calling and conducting meetings [26][27] - Proposals for meetings must be submitted in advance, and decisions require a majority vote from attending directors [39][46] Decision-Making and Voting - Decisions are made through a voting process, where each director has one vote, and specific conditions apply for abstentions and conflicts of interest [45][48] - The board must ensure that decisions comply with legal and regulatory requirements [52] Record Keeping - The board secretary is responsible for maintaining records of meetings, including minutes, attendance, and voting results, for a period of ten years [28][59] Amendments to Rules - The board must revise these rules in response to changes in laws or company charter, with any amendments requiring shareholder approval [63][64]

董事会议事规则 第一章 总 则 第一条 为明确公司董事会的职责权限，规范公司董事会的议事方式和决策 程序，促使公司董事和董事会有效地履行职责，提高公司董事会规范运作和科学 决策水平，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》、《上市公司章程指引》、《上海证券交易所科创板股票上市规则》 （以下简称"《股票上市规则》"）、《上市公司治理准则》及《上海毕得医药科技 股份有限公司章程》（以下简称"公司章程"）等有关规定，制定本规则。 第二章 董事会的组成和职权 第二条 公司依法设立董事会。 上海毕得医药科技股份有限公司 第三条 公司董事会的组成由公司章程作出规定。 第四条 董事会在《公司法》和公司章程规定的范围内依法行使职权。 第五条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （八）法律、行政法规或部门规章规定的其他情形。 董事候选人存在以下情形的，公司应当披露候选人具体情形、拟聘请该候选 人的原因以及是否影响公司规范运作： （一）最近 36 个月内受到中国证监会行政处罚； （二）因贪污、贿赂、侵占财产、挪用财产或者破 ...